Sharemaestro company-news research for Twist Bioscience Corp (TWST), showing current tone, evidence confidence, direct company coverage, sector and industry context, completed price response and the source headlines used on the page. Scores describe published news evidence. Confidence describes the amount, freshness, source breadth and direct company relevance of that evidence. Price context is shown separately.

NASDAQ United States Provisional evidence

Company news sentiment

Latest TWST news and sentiment

Twist Bioscience Corp

Company headlines from the last 30 days, weighted by freshness, relevance, publisher quality and the strength of the wording. Price is shown separately.

Full chart Weekly report Factor research Options activity RSS feed
30-day score52Neutral is 50
Early balanced news score 31/100 evidence confidence 97% direct company focus 30 current stories across 11 publishers
Latest weekly closeUSD 166.99week of 18 Sep 2026
Main news subjectMarket update73/100 share of current news
News data statusPartial24 duplicate stories removed

Current company news

Early balanced news score

30 company-specific stories are available, but there are not yet enough fresh stories from separate publishers for a firm reading.

Observed headline tone54/100 Published 30-day score52/100

Older, less relevant and less reliable stories count for less. Confidence is shown separately.

Latest source headline Twist Bioscience Stock Gains Lilly AI Drug Discovery Partnership Exposure simplywall.st · 21 Sep 2026 07:34

What supports the score

Direct evidence

30 current stories are mapped specifically to TWST.

Source breadth

The score uses 11 publishers rather than depending on one outlet.

What limits the score

Too little evidence

The stories agree, but freshness-weighted evidence is only 0.554.

Confidence

Confidence is 31/100, below the threshold for a firm score.

52/100
News scoreEarly balanced news score
31/100
Confidencethin evidence
97%/100
Company news30 company stories
85/100
Story agreement15/100 difference

News history

Daily score and story count over 30 days

Daily weighted evidence
26 Aug: 1 stories01 Sep: 1 stories04 Sep: 1 stories05 Sep: 1 stories07 Sep: 1 stories08 Sep: 2 stories09 Sep: 4 stories10 Sep: 1 stories15 Sep: 1 stories16 Sep: 4 stories17 Sep: 3 stories19 Sep: 1 stories20 Sep: 1 stories21 Sep: 2 stories 26 Aug: tone 25, 1 stories01 Sep: tone 57, 1 stories04 Sep: tone 50, 1 stories05 Sep: tone 50, 1 stories07 Sep: tone 50, 1 stories08 Sep: tone 38, 2 stories09 Sep: tone 45, 4 stories10 Sep: tone 40, 1 stories15 Sep: tone 60, 1 stories16 Sep: tone 54, 4 stories17 Sep: tone 63, 3 stories19 Sep: tone 59, 1 stories20 Sep: tone 50, 1 stories21 Sep: tone 55, 2 stories 95505
26 Aug10 Sep24 Sep
News scoreStory count50 baseline

Confidence

How reliable the score is

Separate from direction

Confidence uses the amount of news, separate publishers, direct company relevance, freshness and agreement. A high or low score is not automatically reliable.

Amount of evidence11
0.554 after freshness weighting
Source breadth100
11 independent publishers
Company relevance97
share tied directly to this company
Freshness29
recency-weighted evidence
Agreement85
how closely stories agree
Publisher mix79
less reliance on one publisher

Price and news history

Weekly price and news-score history

Early company-news score

Company-specific news is present, but the evidence has not yet earned enough independent, fresh information weight for price confirmation to be treated as a firm signal.

26 completed price weeks19 comparable news-score weeks
One scoring method across the chart.Stored company headlines are recalculated at each weekly point with the current 30-day freshness weighting. Old published snapshots are left unchanged.
27 Mar 2026: close 44.53, indexed 100.003 Apr 2026: close 50.21, indexed 112.810 Apr 2026: close 47.91, indexed 107.617 Apr 2026: close 59.81, indexed 134.324 Apr 2026: close 60.94, indexed 136.901 May 2026: close 60.4, indexed 135.608 May 2026: close 56.85, indexed 127.715 May 2026: close 49.17, indexed 110.422 May 2026: close 60.57, indexed 136.029 May 2026: close 66.87, indexed 150.205 Jun 2026: close 69.22, indexed 155.412 Jun 2026: close 76.17, indexed 171.119 Jun 2026: close 87.56, indexed 196.626 Jun 2026: close 99.84, indexed 224.203 Jul 2026: close 99.24, indexed 222.910 Jul 2026: close 90.635, indexed 203.517 Jul 2026: close 93.85, indexed 210.824 Jul 2026: close 90.27, indexed 202.731 Jul 2026: close 91.55, indexed 205.607 Aug 2026: close 115.67, indexed 259.814 Aug 2026: close 118.57, indexed 266.321 Aug 2026: close 145.59, indexed 326.928 Aug 2026: close 141.38, indexed 317.504 Sep 2026: close 124.72, indexed 280.111 Sep 2026: close 127.22, indexed 285.718 Sep 2026: close 166.99, indexed 375.0 08 May 2026: news score 52, close 56.85, 4 stories5215 May 2026: news score 51, close 49.17, 4 stories22 May 2026: news score 50, close 60.57, 4 stories29 May 2026: news score 50, close 66.87, 4 stories5012 Jun 2026: news score 52, close 76.17, 1 stories19 Jun 2026: news score 50, close 87.56, 2 stories26 Jun 2026: news score 49, close 99.84, 7 stories4903 Jul 2026: news score 50, close 99.24, 11 stories10 Jul 2026: news score 52, close 90.635, 14 stories17 Jul 2026: news score 55, close 93.85, 19 stories5524 Jul 2026: news score 63, close 90.27, 23 stories31 Jul 2026: news score 56, close 91.55, 32 stories07 Aug 2026: news score 57, close 115.67, 68 stories5714 Aug 2026: news score 55, close 118.57, 83 stories21 Aug 2026: news score 59, close 145.59, 102 stories28 Aug 2026: news score 53, close 141.38, 95 stories5304 Sep 2026: news score 52, close 124.72, 61 stories11 Sep 2026: news score 45, close 127.22, 53 stories18 Sep 2026: news score 51, close 166.99, 36 stories51 Price index 408.0 237.5 67.0 News score 100 50 0
27 Mar23 Jun18 Sep
Weekly close, indexedSentiment score
26-week price+275.0%latest close 166.99
News score change-1first to latest comparable week
One-week response+31.3%Price confirming higher
Fair-value position+262.7%Materially above fair value
WeekNews scoreCloseWeekly move
18 Sep 202651USD 166.99+31.3%
11 Sep 202645USD 127.22+2.0%
04 Sep 202652USD 124.72-11.8%
28 Aug 202653USD 141.38-2.9%
21 Aug 202659USD 145.59+22.8%
14 Aug 202655USD 118.57+2.5%
07 Aug 202657USD 115.67+26.3%
31 Jul 202656USD 91.55+1.4%
Provisional evidence

News subjects

What is shaping the score

Market update
Earnings5911 stories · 37%
Market update5211 stories · 37%
Analyst action313 stories · 10%
Deals and strategy562 stories · 7%
Regulatory and legal271 stories · 3%
Guidance591 stories · 3%
Balance sheet501 stories · 3%

Source mix

Where the evidence comes from

79/100 independence
simplywall.st575 stories · 17%
Stock Titan404 stories · 13%
Investing.com513 stories · 10%
finance.yahoo.com512 stories · 7%
Trefis502 stories · 7%
dars.gov.et251 stories · 3%
Claim Depot271 stories · 3%

Recurring subjects

Subjects appearing most often

Current evidence
Life Sciences10Earnings9Financial Markets6Finance6Biotech6Technology5AI3Healthcare2Drug Discovery2Antibody Discovery2

Earlier readings

How the score has changed

52 comparable readings · 75 days
Past and present use the same method.Each point recalculates the previous 30 days of stored company headlines with today's scoring rules. The original stored snapshots remain unchanged.
Comparable move+052 to 52 · Broadly stable
Observed range45–6350 is the neutral baseline
Evidence depth30stories at latest stored reading · +17
Confidence30/100Provisional · +2
09 Jul50 neutral23 Sep 10:59
ConstructiveBalanced or withheldCautious

Changes in the stored score

Scores are rebuilt from stored headlines with the current 30-day method. Days with no change are collapsed.

ObservedScoreMoveConfidenceStoriesStatus
23 Sep 10:5952+030/100 (-2)30 (-1)Provisional
21 Sep 23:5952+032/100 (-1)31 (+2)Provisional
20 Sep 23:5952+033/100 (-2)29 (-2)Provisional
19 Sep 23:5952+035/100 (0)31 (-19)Provisional
17 Sep 23:5952+435/100 (+7)50 (+1)Provisional
16 Sep 23:5948+128/100 (+1)49 (+3)Provisional
15 Sep 23:5947+227/100 (-9)46 (-12)Provisional
10 Sep 23:5945+036/100 (-1)58 (-1)Provisional

Source headlines

The news behind the score

Showing 1-30 of 30

Only company-specific stories enter this score. The latest 30 days are shown newest first, with newer stories weighted more heavily and duplicate coverage combined.

#157Tone
simplywall.stDirect company coverageStored article

Twist Bioscience Stock Gains Lilly AI Drug Discovery Partnership Exposure

Twist Bioscience Corporation (NASDAQ:TWST) is on the cusp of gaining significant exposure to the rapidly evolving artificial intelligence (AI)-driven drug discovery ecosystem. On September 16, the company confirmed a strategic partnership with Lilly TuneLab, a platform created by Eli Lilly and Company (NYSE:LLY). As part of the strategic partnership, Twist will provide antibody characterization data services for TuneLab. It will also provide data to support AbLab, an antibody developability prediction model, and high-throughput wet-lab data that can help train and improve those models. Through

AIBiotechDrug DiscoveryExperimental DataPartnershipRevenue Growth
Published
21 Sep 2026 07:34
News subject
Earnings
Why this score
Positive financial language
Company focus
Shared story · 78%
How it is used
Direct company coverage
Story strength
Medium · 43/100
30-day weight
11.7% of the score · 2.1d old
Duplicates
2 consolidated
#2—Not directional
TrefisDirect company coverageScored from headline

Twist Bioscience Stock: 7 Straight Green Days, Up 33%

Published
21 Sep 2026 05:21
News subject
Market update
Why this score
The headline reports news without a clear direction
Company focus
Main company · 100%
How it is used
Shown as company news · not used in the score
Story strength
Not directional
30-day weight
None · 2.2d old
Duplicates
2 consolidated
#3—Not directional
The Chronicle-JournalDirect company coverageScored from headline

Twist Bioscience Corporation - Common Stock (NQ: TWST

Published
20 Sep 2026 03:11
News subject
Market update
Why this score
The headline reports news without a clear direction
Company focus
Main company · 100%
How it is used
Shown as company news · not used in the score
Story strength
Not directional
30-day weight
None · 3.3d old
Duplicates
1 consolidated
#660Tone
StocksToTradeDirect company coverageScored from headline

Twist Bioscience Stock Jumps As Lilly AI Deal Fuels Momentum

Published
17 Sep 2026 16:33
News subject
Deals and strategy
Why this score
Positive market reaction
Company focus
Main company · 100%
How it is used
Direct company coverage
Story strength
Medium · 48/100
30-day weight
13.5% of the score · 5.8d old
Duplicates
1 consolidated
#7—Not directional
finance.yahoo.comDirect company coverageStored article

Twist Bioscience (TWST) Is Up 14.0% After Lilly AI Drug Discovery Tie-Up Is Announced - Has The Bull Case Changed?

On 16 September 2026, Twist Bioscience announced an agreement with Lilly TuneLab, under which Twist will provide antibody characterization data services using preferred Twist protocols to generate high-quality wet lab data that feed Lilly's AI/ML drug discovery models. This collaboration effectively plugs Twist's DNA and antibody capabilities into Lilly's AI-driven discovery ecosystem, potentially deepening Twist's role in data-rich, AI-enhanced antibody development workflows across the biopharma industry. We'll now examine how Twist's integration into Lilly's AI-enabled TuneLab platform could

AIAntibody DiscoveryBiopharmaEarningsEquity DilutionFinancial Markets
Published
17 Sep 2026 10:10
News subject
Earnings
Why this score
The headline reports news without a clear direction
Company focus
Shared story · 78%
How it is used
Shown as company news · not used in the score
Story strength
Not directional
30-day weight
None · 6.0d old
Duplicates
1 consolidated
#8—Not directional
Investing.comDirect company coverageStored article

Twist Bioscience stock rises on Eli Lilly partnership deal

Twist Bioscience Corp (NASDAQ:TWST) shares climbed 3% following the announcement of a partnership with Eli Lilly and Company's TuneLab. Under the agreement, Twist will provide antibody characterization data services for TuneLab, aiming to accelerate biotech innovation by connecting experimental data with AI-enabled drug discovery. This collaboration will allow TuneLab users to access Twist's services with preferred protocols and pricing, contributing to more efficient antibody drug discovery.

Life SciencesTechnology
Published
16 Sep 2026 18:05
News subject
Deals and strategy
Why this score
Positive market reaction, Large positive market reaction
Company focus
Main company · 100%
How it is used
Shown as company news · not used in the score
Story strength
Not directional
30-day weight
None · 6.7d old
Duplicates
1 consolidated
#9—Not directional
FinvizDirect company coverageStored article

Twist Bioscience Joins Lilly TuneLab to Advance Antibody Drug Discovery

Antibody characterization data generated by Twist supports TuneLab AI models designed to accelerate antibody discovery SOUTH SAN FRANCISCO, Calif., September 16, 2026--(BUSINESS WIRE)--Twist Bioscience Corporation (NASDAQ: TWST), a mid-cap growth and value biotech company, today announced an agreement with Lilly TuneLab, a collaborative AI/ML drug discovery platform created by Eli Lilly and Company (Lilly). Twist is a provider of antibody characterization data services for TuneLab, including for AbLab, an antibody developability prediction model. TuneLab was created to accelerate biotech innov

AI MlAntibody DiscoveryBiotech
Published
16 Sep 2026 14:53
News subject
Market update
Why this score
The headline reports news without a clear direction
Company focus
Shared story · 78%
How it is used
Shown as company news · not used in the score
Story strength
Not directional
30-day weight
None · 6.8d old
Duplicates
1 consolidated
#10—Not directional
seekingalpha.comDirect company coverageStored article

Twist Bio, and Gingko rise after agreements with Lilly TuneLab

[Two coloured ropes knotted together] Richard Drury Twist Bioscience (TWST [https://seekingalpha.com/symbol/TWST]) and Ginkgo Bioworks (DNA [https://seekingalpha.com/symbol/DNA]) traded higher on Wednesday after announcing agreements with Lilly TuneLab, a collaborative drug discovery platform established by Eli Lilly (LLY [https://seekingalpha.com/symbol/LLY]). As part of its agreement with Lilly, Twist Bio (TWST [https://seekingalpha.com/symbol/TWST]) said that it will provide antibody characterization data services to TuneLab companies accessing AI/ML drug discovery models trained on Lilly-o

AI MlBiotechDrug Discovery
Published
16 Sep 2026 14:36
News subject
Market update
Why this score
The headline reports news without a clear direction
Company focus
Shared story · 78%
How it is used
Shown as company news · not used in the score
Story strength
Not directional
30-day weight
None · 6.8d old
Duplicates
1 consolidated
#1157Tone
finance.yahoo.comDirect company coverageStored article

AI and Next-Gen Sequencing Strengthens Twist Bioscience Corp. (TWST)

Parnassus Investments, an investment management company, released the "Parnassus Growth Equity Fund" second-quarter 2026 investor letter. The letter can be downloaded here. During the quarter, the Fund (Investor Shares) returned 17.49% (net of fees), outperforming the Russell 1000 Growth Index's 16.74%. Holdings in Information Technology and Consumer Discretionary sectors boosted relative returns, while Communication Services and Financials holdings detracted. For the year-to-date period, the Fund returned 6.17% (net of fees), outperforming the Russell 1000 Growth's 5.33%. The firm remains con

AIBiotechGrowth Stocks
Published
16 Sep 2026 13:59
News subject
Market update
Why this score
Positive financial language
Company focus
Main company · 100%
How it is used
Direct company coverage
Story strength
Low · 30/100
30-day weight
1.3% of the score · 6.9d old
Duplicates
1 consolidated
#1260Tone
simplywall.stDirect company coverageScored from headline

Twist Bioscience (TWST) Shares Climbed, So What Is Catching Investors' Attention?

Published
15 Sep 2026 05:41
News subject
Market update
Why this score
Positive market reaction
Company focus
Main company · 100%
How it is used
Direct company coverage
Story strength
Low · 34/100
30-day weight
1% of the score · 8.2d old
Duplicates
1 consolidated
#1340Tone
Kalkine MediaDirect company coverageStored article

Twist Bioscience HR SVP Paula Green Sells Shares to Cover RSU Tax Withholding

Paula Green, Senior Vice President of Human Resources at Twist Bioscience Corp, sold 907 shares of company common stock on September 8, 2026. This transaction, valued at $122.624 per share, was not a discretionary trade but a mandatory "sell to cover" sale to meet tax withholding obligations associated with the vesting of Restricted Stock Units (RSUs). After the sale, Green directly holds 117,014 shares of Twist Bioscience.

EarningsFinance
Published
10 Sep 2026 21:26
News subject
Earnings
Why this score
Institutional or insider selling
Company focus
Main company · 100%
How it is used
Direct company coverage
Story strength
Medium · 40/100
30-day weight
6.3% of the score · 12.6d old
Duplicates
1 consolidated
#1426Tone
Investing.comDirect company coverageStored article

BWS Financial initiates Twist Bioscience stock with sell rating

BWS Financial initiated coverage on Twist Bioscience (NASDAQ:TWST) with a sell rating and a price target of $45.00, citing its significant premium compared to competitors and overvaluation. Analyst Hamed Khorsand highlighted pricing pressure from integrated incumbents, the non-commercial nature of a recent stock-driving research evaluation, and increasing insider selling. Despite a remarkable stock performance over the past year, the company is not expected to be profitable this year.

EarningsFinancial MarketsLife SciencesTechnology
Published
09 Sep 2026 14:28
News subject
Analyst action
Why this score
Analyst downgrade, Sell Rating
Company focus
Main company · 100%
How it is used
Direct company coverage
Story strength
Medium · 48/100
30-day weight
2.2% of the score · 13.9d old
Duplicates
1 consolidated
#15—Not directional
BioSpaceDirect company coverageStored article

Twist Bioscience to Present at Baird 2026 Global Healthcare Conference

Twist Bioscience announced that its CEO, Emily M. Leproust, Ph.D., and CFO, Adam Laponis, will participate in a fireside chat at the Baird 2026 Global Healthcare Conference. The event is scheduled for September 15, 2026, at 1:25 pm Eastern Time in New York City and will be webcast live. A replay of the chat will be available for 30 days on the company's investor relations website.

BiotechConferenceEarningsFinancial MarketsHealthcareLife Sciences
Published
09 Sep 2026 13:52
News subject
Earnings
Why this score
The headline reports news without a clear direction
Company focus
Main company · 100%
How it is used
Shown as company news · not used in the score
Story strength
Not directional
30-day weight
None · 13.9d old
Duplicates
1 consolidated
#16—Not directional
MT NewswiresDirect company coverageScored from headline

UBS Initiates Coverage on Twist Bioscience With Neutral Rating, $144 Price Target

Published
09 Sep 2026 12:17
News subject
Analyst action
Why this score
The headline reports news without a clear direction
Company focus
Main company · 100%
How it is used
Shown as company news · not used in the score
Story strength
Not directional
30-day weight
None · 13.9d old
Duplicates
1 consolidated
#17—Not directional
simplywall.stDirect company coverageScored from headline

Twist Bioscience (TWST) Stock Looks Undervalued On Cash Flow But Overvalued On Sales

Published
09 Sep 2026 07:00
News subject
Balance sheet
Why this score
Positive valuation view, Negative valuation view
Company focus
Main company · 100%
How it is used
Shown as company news · not used in the score
Story strength
Not directional
30-day weight
None · 14.2d old
Duplicates
1 consolidated
#1869Tone
Insider MonkeyDirect company coverageStored article

Twist Bioscience (TWST) Rallied as AI and Pharma Drive DNA Demand

Artisan Partners, an investment management company, released its second-quarter 2026 investor letter for the "Artisan Mid Cap Fund". The letter can be downloaded here. Global equities rebounded sharply in Q2 2026, recovering from March lows as resilient economic data, strong corporate earnings, and continued AI investment improved investor sentiment despite inflation concerns, delayed rate cuts, and geopolitical uncertainty. The portfolio generated strong absolute returns and outperformed the Russell Midcap® Growth Index, benefiting from semiconductor exposure within IT and strong stock select

BiotechConsumer DiscretionaryEarningsHealthcareSemiconductors
Published
08 Sep 2026 12:53
News subject
Earnings
Why this score
Operating growth
Company focus
Main company · 100%
How it is used
Direct company coverage
Story strength
Medium · 48/100
30-day weight
5.4% of the score · 14.9d old
Duplicates
1 consolidated
#1927Tone
Claim DepotDirect company coverageStored article

Claim your share of the $17 million Twist Bioscience securities class action settlement

Investors who purchased Twist Bioscience common stock between December 20, 2018, and November 15, 2022, or in its December 2020 secondary offering, may be eligible for a cash payment from a $17 million securities class action settlement. The lawsuit alleged that Twist Bioscience made false and misleading statements about its production process, product quality, and accounting, leading to inflated stock prices and investor losses. Eligible class members must submit a claim by November 17, 2026, with the estimated average net recovery being $0.22 per affected share.

FinanceLife Sciences
Published
08 Sep 2026 10:44
News subject
Regulatory and legal
Why this score
Legal or regulatory risk, Dilution risk
Company focus
Main company · 100%
How it is used
Direct company coverage
Story strength
Medium · 57/100
30-day weight
15.3% of the score · 15.0d old
Duplicates
1 consolidated
#20—Not directional
TrefisDirect company coverageScored from headline

Twist Bioscience Stock: 6 Straight Red Days, Down 19%

Published
07 Sep 2026 06:57
News subject
Market update
Why this score
The headline reports news without a clear direction
Company focus
Main company · 100%
How it is used
Shown as company news · not used in the score
Story strength
Not directional
30-day weight
None · 16.2d old
Duplicates
1 consolidated
#21—Not directional
Investing.com South AfricaDirect company coverageStored article

Cathie Wood’s ARK sees major stock moves with Robinhood and Twist Bioscience By Investing.com

Cathie Wood's ARK ETFs made several significant trades on Friday, September 4th, 2026, increasing its stake in Robinhood Markets, Veracyte, and Intellia Therapeutics. Conversely, ARK reduced its positions in Twist Bioscience Corporation and Tempus AI. These moves reflect ARK's continued focus on technology, healthcare, and innovation.

BlockchainFinancial MarketsLife SciencesTechnology
Published
05 Sep 2026 00:58
News subject
Market update
Why this score
The headline reports news without a clear direction
Company focus
Main company · 100%
How it is used
Shown as company news · not used in the score
Story strength
Not directional
30-day weight
None · 18.4d old
Duplicates
1 consolidated
#2540Tone
GuruFocusDirect company coverageStored article

Twist Bioscience Corp (TWST) Stock Up 7.5% but GF Value Says Overvalued -- GF Score: 69/100

Twist Bioscience Corp (TWST) stock rose 7.5% today to $151.42, yet GuruFocus's GF Value™ indicates it is 188.0% overvalued compared to its fair value of $52.58. The company shows strong growth (10/10) but struggles with profitability (3/10) and is considered highly overvalued (1/10). Notably, insiders have sold $64.5M worth of shares over the past year with no buying activity, raising concerns about future prospects.

Financial MarketsLife Sciences
Published
25 Aug 2026 23:47
News subject
Market update
Why this score
Negative valuation view, Institutional or insider selling
Company focus
Main company · 100%
How it is used
Direct company coverage
Story strength
Low · 33/100
30-day weight
<0.1% of the score · 28.5d old
Duplicates
1 consolidated
#2640Tone
Stock TitanDirect company coverageStored article

Twist Bioscience (NASDAQ: TWST) COO sells shares in tax-withholding trade

Twist Bioscience Corp (TWST) President and COO Patrick John Finn sold 4,046 shares of common stock on August 21, 2026, for a total of $563,165. This transaction was a mandatory "sell to cover" to satisfy tax withholding obligations on vested Restricted Stock Units, not a discretionary trade. Following the sale, Finn directly holds 210,802 shares of TWST.

EarningsFinance
Published
25 Aug 2026 19:41
News subject
Earnings
Why this score
Institutional or insider selling
Company focus
Main company · 100%
How it is used
Direct company coverage
Story strength
Medium · 36/100
30-day weight
0.6% of the score · 28.6d old
Duplicates
1 consolidated
#2740Tone
Stock TitanDirect company coverageStored article

Twist Bioscience (NASDAQ: TWST) CFO sells shares to cover taxes

Twist Bioscience's CFO, Adam Laponis, sold 1,965 shares of common stock at $139.066 per share on August 21, 2026. This transaction was not a discretionary trade but rather a "sell to cover" action to satisfy tax withholding obligations related to the vesting of Restricted Stock Units. Following this sale, Laponis directly holds 108,633 shares of the company's common stock.

EarningsFinanceLife SciencesTechnology
Published
25 Aug 2026 19:41
News subject
Earnings
Why this score
Institutional or insider selling
Company focus
Main company · 100%
How it is used
Direct company coverage
Story strength
Medium · 36/100
30-day weight
0.7% of the score · 28.6d old
Duplicates
1 consolidated
#2840Tone
Stock TitanDirect company coverageStored article

Twist Bioscience (TWST) CEO trims stake in tax-driven sale

Twist Bioscience CEO Emily M. Leproust sold 6,639 shares of common stock on August 21, 2026, for $139.066 per share. This sale was a mandatory "sell to cover" transaction to fulfill tax withholding obligations on vested Restricted Stock Units, not a discretionary trade. Following the sale, Leproust directly holds 812,299 common shares, in addition to various employee stock options.

EarningsEconomy FiscalFinanceLife Sciences
Published
25 Aug 2026 19:41
News subject
Earnings
Why this score
Institutional or insider selling
Company focus
Main company · 100%
How it is used
Direct company coverage
Story strength
Medium · 36/100
30-day weight
0.7% of the score · 28.6d old
Duplicates
1 consolidated
#29—Not directional
Stock TitanDirect company coverageStored article

Twist Bioscience (NASDAQ: TWST) officer sets 854-share sale tied to equity taxes

Robert F. Werner, an officer at Twist Bioscience Corp (TWST), has filed a Rule 144 notice to sell 854 shares of common stock. This proposed sale is connected to restricted stock vesting, with a portion of the proceeds intended to cover tax obligations from a vested equity award. The filing also notes several previous stock sales by Werner over the last three months.

FinanceFinancial MarketsLife Sciences
Published
24 Aug 2026 19:42
News subject
Market update
Why this score
Institutional or insider selling
Company focus
Main company · 100%
How it is used
Shown as company news · not used in the score
Story strength
Not directional
30-day weight
None · 29.6d old
Duplicates
1 consolidated
#30—Not directional
Investing.comDirect company coverageStored article

Guggenheim reiterates Twist Bioscience stock rating on AI drug discovery potential

Guggenheim has reiterated a Buy rating and a $107.00 price target for Twist Bioscience (NASDAQ:TWST), citing the company's significant opportunities in AI-enabled drug discovery. Despite the stock's 409% surge over the past year and current trading near its 52-week high, InvestingPro data suggests it may be overvalued. Twist Bioscience expects triple-digit order growth in this sector for the current and next year, although short-seller Scorpion Capital has raised concerns regarding the company's role in an AI partnership with Anthropic.

EarningsLife SciencesTechnology
Published
24 Aug 2026 11:42
News subject
Analyst action
Why this score
Buy Rating, Positive market reaction, Negative valuation view
Company focus
Main company · 100%
How it is used
Shown as company news · not used in the score
Story strength
Not directional
30-day weight
None · 30.0d old
Duplicates
1 consolidated

Earlier company news

TWST news archive

156 older headlines

Stored newest first for historical research. It starts after the newest three pages above and then continues through older news. Each archive page is loaded only when it is opened.

Older news is kept in the archive

There are 156 older TWST headlines. Open one page at a time when you need them.

Open older archive

Provider matches checked

Provider mentions not used in the score

6 not scored

A news provider linked these stories to TWST, but the headline and available text are not mainly about Twist Bioscience Corp. They are kept here for transparency and do not affect the score, confidence, history or wider market totals.

Provider mentions are kept separate

Open the list to see which provider matches were checked and left out of TWST sentiment.

Open provider mentions

How the page works

How to read the score

The score shows direction

It describes the weighted balance of qualifying headlines. A score of 50 can mean balanced news or that there is not enough evidence; the status label explains which.

Confidence is separate

Confidence measures depth, source breadth, direct relevance, freshness and agreement. It does not rise merely because the tone is extreme.

Price is confirmation

Weekly price response, trend and fair-value position test whether the market is accepting or rejecting the news. They never rewrite the news score.

What the page does

It measures news already published. It is not a forecast, recommendation or price target.

Evidence context